Analytical Data
-
Gene name
SSX1
- Application
-
Alternative Names
(Cancer/testis antigen 5.1)(CT5.1)(Synovial sarcoma, X breakpoint 1)
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16384
-
Expression Region
1-188aa
-
Molecular Weight
34.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SSX1, a member of the SSX family of cancer/testis antigens, is primarily expressed in the testis, but aberrantly found in various tumors, making it a candidate for cancer immunotherapy. Originally identified as a gene upregulated in melanoma, SSX1 plays a role in immune evasion and tumor progression. Research has shown that SSX1 can elicit specific immune responses, particularly through T-cell recognition, which underscores its potential as a target for vaccine development. Its expression in tumors but not in normal tissues presents a unique opportunity for creating targeted therapies that minimize damage to healthy cells. The study of SSX1 recombinant proteins focuses on understanding its structure and function, optimizing its use in immunotherapy, and exploring its mechanisms of action in tumor biology. Furthermore, as a marker for cancer diagnostics, SSX1's immunogenic properties hold promise for advancing personalized medicine approaches in oncology, stimulating both humoral and cellular immune responses. Researchers are investigating its role in various malignancies beyond melanoma, including lung cancer and other solid tumors, to evaluate its universal applicability as a therapeutic target. Overall, the advancement of SSX1 recombinant protein studies aims to harness the immune system to discriminate between cancerous and normal cells, paving the way for innovative treatment strategies that could improve patient outcomes in malignant diseases.
